SLC5A2 and type 2 diabetes mellitus: In the past decade, inhibitor of dipeptylpeptidase 4 (iDPP4) and sodium-glucose cotransporter-2 (SGLT-2) have been included in T2DM treatments, either monotherapy or in combination therapy, and currently represent the leading T2DM therapies [14,15,16].